Glucagon-like peptide-1: difference between revisions
Diff·revision 13 → 14·00:43, 17 Nov 2024
Difference between revision 13 and revision 14 of Glucagon-like peptide-1. 10 lines changed; the page grew by 341 bytes.
| Revision 13 — 00:10, 27 Oct 2024 SatietySunniva (talk) add the postprandial time course with its units 7,886 bytes +487 | Revision 14 — 00:43, 17 Nov 2024 SatietySunniva (talk) fix hyphenation per PP:MOS 8,227 bytes +341 | ||
|---|---|---|---|
| 12 | | Monoisotopic mass = ≈3,297 Da (7–36 amide) | 12 | | Monoisotopic mass = ≈3,297 Da (7–36 amide) |
| 13 | | Sequence position = Proglucagon 78–107 | 13 | | Sequence position = Proglucagon 78–107 |
| + | 14 | <!-- Pharmacokinetics --> | |
| + | 15 | | Plasma half-life = 1.5–2 minutes | |
| + | 16 | | Primary inactivation = [[Dipeptidyl peptidase-4|DPP-4]] cleavage at Ala<sup>8</sup> | |
| + | 17 | | Secondary clearance = Renal; neutral endopeptidase | |
| 14 | }} | 18 | }} |
| 15 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} | 19 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} |
| ⋮ | ⋮ | ||
| 62 | <ref name="kreymann1987">Kreymann B, Williams G, Ghatei MA, Bloom SR. "Glucagon-like peptide-1 7–36: a physiological incretin in man." ''The Lancet'' 2(8571):1300–1304 (1987). PMID 2890903.</ref> | 66 | <ref name="kreymann1987">Kreymann B, Williams G, Ghatei MA, Bloom SR. "Glucagon-like peptide-1 7–36: a physiological incretin in man." ''The Lancet'' 2(8571):1300–1304 (1987). PMID 2890903.</ref> |
| 63 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> | 67 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> |
| + | 68 | ||
| + | 69 | == See also == | |
| + | 70 | * [[GLP-1 receptor]] | |
| + | 71 | * [[Glucose-dependent insulinotropic polypeptide]] | |
| + | 72 | * [[Incretin effect]] | |
| + | 73 | * [[Dipeptidyl peptidase-4]] | |
| 64 | 74 | ||
| 65 | {{DEFAULTSORT:Glucagon-like peptide-1}} | 75 | {{DEFAULTSORT:Glucagon-like peptide-1}} |